SCHEMBL24680916

SCHEMBL24680916

COCCN(C)[C@@H]1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 4/20 0.48
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
HSD11B1 P28845 1/20 0.45
PIK3CD O00329 1/20 0.44
GPR119 Q8TDV5 6/20 0.42
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
HPGD P15428 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
RECQL P46063 1/20 0.39
EPHX1 P07099 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31208730 1.00 USP30 (0.48) USP30JAK2JAK1HSD11B1PIK3CD
SCHEMBL24680917 1.00 USP30 (0.48) USP30JAK2JAK1HSD11B1PIK3CD
SCHEMBL1088735 0.92 MEN1 (0.47) USP30JAK2JAK1HSD11B1PIK3CD
SCHEMBL393481 0.92 HPGD (0.46) USP30JAK2JAK1GPR119HPGD
SCHEMBL21494393 0.89 NR1H2 (0.46) USP30JAK2JAK1HSD11B1PIK3CD
SCHEMBL18780593 0.87 USP30 (0.47) USP30JAK2JAK1HSD11B1GPR119
SCHEMBL34473959 0.86 USP30 (0.50) USP30JAK2JAK1HSD11B1PIK3CD
SCHEMBL16854650 0.85 GPR119 (0.43) USP30JAK2JAK1GPR119HPGD
SCHEMBL19156899 0.84 USP30 (0.46) USP30JAK2JAK1HSD11B1GPR119
SCHEMBL24681334 0.83 USP30 (0.52) USP30JAK2JAK1HSD11B1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-10-17 US disclosed
WO-2022226667-A1 SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed
WO-2022226667-A1 SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed
WO-2022226668-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) CMPK1, WNK1, AAK1 USP30 3239/4885JAK2 333/4885JAK1 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.